問卷

TPIDB > Principal Investigator

Principal Investigator


Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of Thoracic Surgery

Division of Hematology & Oncology

Division of General Internal Medicine

Division of Thoracic Medicine

Linkou Chang Gung Medical Foundation (在職)

Division of Thoracic Medicine

更新時間:2023-09-19

林孟志
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

158Cases

2007-09-01 - 2009-03-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2008-10-22 - 2010-10-22

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2009-07-01 - 2012-08-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2015-11-01 - 2017-10-31

Phase III

An Open-label, Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer Tumors with EGFR Activating Mutations
  • Condition/Disease

    Stage IIIB/IV Non-small Cell Lung Cancer Tumors with EGFR Activating Mutations

  • Test Drug

    ASP8273

Participate Sites
9Sites

Terminated9Sites

邱昭華
Taipei Veterans General Hospital

Division of Hematology & Oncology

楊政達
Linkou Chang Gung Medical Foundation

Division of Thoracic Medicine

2015-02-25 - 2025-12-31

Phase III

A PHASE III PROSPECTIVE DOUBLE BLIND PLACEBO CONTROLLED RANDOMIZED STUDY OF ADJUVANT MEDI4736 IN COMPLETELY RESECTED NON-SMALL CELL LUNG CANCER
  • Condition/Disease

    COMPLETELY RESECTED NON-SMALL CELL LUNG CANCER

  • Test Drug

    MEDI4736

Participate Sites
13Sites

Not yet recruiting2Sites

Recruiting3Sites

Terminated8Sites

2012-07-01 - 2019-08-31

Phase II/III

A Randomized, Double-Blind, Active Drug Controlled Study to Assess the Efficacy of HUEXC030 as Add-on Excipient to Eradicate Anti-Tuberculosis Drugs Induced Liver Injury in Subjects with Pulmonary Tuberculosis
  • Condition/Disease

    A Randomized, Double-Blind, Active Drug Controlled Study to Assess the Efficacy of HUEXC030 as Add-on Excipient to Eradicate Anti-Tuberculosis Drugs Induced Liver Injury in Subjects with Pulmonary Tuberculosis

  • Test Drug

    Isoniazid tablet formulated with excipient HUEXC030

Participate Sites
13Sites

Terminated13Sites

2014-03-01 - 2019-08-26

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites